Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

VIP Overview, Dosing & Safety | Peptide Database

VIP (Vasoactive Intestinal Polypeptide) Vasoactive Intestinal Peptide | Neuropeptide Community Research Join others researching VIP — share findings, ask questions, and learn from real experiences Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropep

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

VIP (Vasoactive Intestinal Polypeptide)

Vasoactive Intestinal Peptide | Neuropeptide

Community Research

Join others researching VIP — share findings, ask questions, and learn from real experiences

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions.

VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.

Molecular Data

Histidine

Position 1

Serine

Position 2

Aspartic Acid

Position 3

Alanine

Position 4

Valine

Position 5

Phenylalanine

Position 6

Threonine

Position 7

Position 8

Asparagine

Position 9

Tyrosine

Position 10

Position 11

Arginine

Position 12

Leucine

Position 13

Position 14

Lysine

Position 15

Glutamine

Position 16

Methionine

Position 17

Position 18

Position 19

Position 20

Position 21

Position 22

Position 23

Position 24

Position 25

Isoleucine

Position 26

Position 27

Position 28

NH2

Position 29

Research Indications

VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity.

Dilates peripheral blood vessels through NO-dependent mechanisms above 100 pmol doses.

Coronary vasodilation with positive inotropic and chronotropic effects on the heart.

Promising therapeutic target for Alzheimer's, Parkinson's, and other neurological disorders.

Potential therapeutic target being researched for ASD.

Produced in suprachiasmatic nuclei; involved in circadian regulation.

Promotes insulin secretion in glucose-dependent manner via VPAC2; low hypoglycemia risk.

Potent anti-inflammatory effects useful in IBD and autoimmune conditions.

Therapeutic potential for pulmonary and systemic sarcoidosis.

Dosing Protocols

VIP has a very short half-life of approximately 2 minutes in blood, requiring careful dosing strategies. Subcutaneous or intravenous administration. Rapid degradation limits bioavailability; analogs like stearyl-Nle17-VIP (SNV) are 100-fold more potent.

General use

50-100 mcg

1-2x daily

SubQ or IV

Research protocols

100-200 mcg

As directed

Reconstitution Instructions

Bacteriostatic water (BAC)

Insulin syringes

Alcohol swabs

Peptide vial

Sterile work surface

1 Clean work area and hands thoroughly

2 Calculate required BAC water volume

3 Draw BAC water into syringe

4 Inject slowly down vial side

5 Gently swirl until dissolved (never shake)

6 Use promptly due to short stability

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Vasodilation (flushing, warmth)

Hypotension

Increased heart rate

Gastrointestinal effects (diarrhea possible)

Headache

Stop Signs - Discontinue if:

Severe hypotension

Allergic reaction symptoms

Severe diarrhea

Cardiac arrhythmias

Contraindications

VIPoma or related tumors

Pregnancy or breastfeeding

Severe cardiac conditions

Quality Checklist

Good Signs

White lyophilized powder

Clear solution after reconstitution

Intact vacuum seal

Warning Signs

Use quickly after reconstitution (unstable)

Bad Signs

Discolored powder

Cloudy solution

Particulates visible

Frequently Asked Questions

How effective is VIP for pulmonary hypertension and can it replace conventional treatments?

VIP inhalation showed striking efficacy with increased mixed venous oxygen saturation and exercise capacity in pulmonary hypertension patients. However, it's complementary to conventional therapy rather than a replacement - the very short 2-minute half-life requires frequent dosing, making it challenging for long-term use without newer stabilized analogs.

Does VIP cause dangerous hypotension or can it be used safely in most patients?

VIP's vasodilation can cause hypotension and flushing, especially at higher doses. Careful dose titration and patient monitoring are essential. Patients with baseline hypotension or severe cardiac conditions should avoid use, but mild transient vasodilation is manageable in most populations with proper medical supervision.

Why is VIP rarely used clinically if research shows such promise?

VIP's extremely short 1-2 minute half-life makes it impractical for routine clinical use - requiring constant infusions or multiple daily injections. Stabilized analogs (like stearyl-Nle17-VIP) are 100-fold more potent but rarely available outside research settings. Limited commercial development has restricted clinical availability despite strong research foundation.

Can VIP improve insulin secretion for diabetes without causing hypoglycemia?

Yes, VIP promotes glucose-dependent insulin secretion via VPAC2 receptors, meaning it only stimulates insulin when blood glucose is elevated. This glucose-dependent mechanism makes hypoglycemia risk very low compared to other insulin secretagogues, making VIP theoretically safer for diabetes support.

References

VIP inhalation showed striking efficacy with increased mixed venous oxygen saturation and exercise capacity.

VIP promotes glucose-dependent insulin secretion via VPAC2, reducing hypoglycemia risk.

VIP and receptors are promising therapeutic targets for AD, PD, and autism spectrum disorders.

Comprehensive review of VIP receptor signaling and therapeutic applications.

Related Peptides

No known negative interactions; different mechanisms.

Both have anti-inflammatory properties.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Tamoxifen — share findings, ask questions, and learn from real experiences Tamoxifen is a first-generation selective estrogen receptor modulator (SERM) that has been in clinical use since the 1970s. It is FDA-approved for the treatment and prevention of estrogen receptor-positive breast cancer and remains one of the most widely prescribed cancer therapies worldwide. In the context of performance enhancement, tamoxifen is used extensively for post-cycle therapy (PCT) to restore the hypothalamic-pituitary-testicular axis after suppression from anabolic steroids, and for on-cycle gynecomastia prevention by blocking estrogen receptors in breast tissue. Tamoxifen acts as an estrogen antagonist in breast and hypothalamic tissue while functioning as a partial estrogen agonist in bone, the uterus, and the cardiovascular system. Its active metabolite endoxifen, produced via CYP2D6 metabolism, is responsible for much of its pharmacological activity. Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling. At the hypothalamus and anterior pituitary, this antagonism removes estrogen-driven negative feedback on GnRH secretion, leading to increased pulsatile GnRH release and subsequent elevation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The rise in LH stimulates Leydig cell testosterone production, which is the basis for its use in post-cycle therapy. In bone tissue, tamoxifen acts as a partial estrogen agonist, providing a protective effect on bone mineral density. Tamoxifen is a prodrug that requires hepatic metabolism via CYP3A4 and CYP2D6 to generate its active metabolites, particularly endoxifen, which has approximately 100-fold greater affinity for the estrogen receptor than the parent compound.

Source: peptide-db.com ↗

Community Research

Join others researching Minoxidil — share findings, ask questions, and learn from real experiences Minoxidil is an FDA-approved vasodilator originally developed in the 1970s as an oral antihypertensive medication. Its hair growth properties were discovered as a side effect, and topical formulations (2% and 5%) were subsequently approved for the treatment of androgenetic alopecia. It remains one of only two FDA-approved treatments for pattern hair loss and is available over the counter in most countries. In recent years, off-label oral minoxidil at low doses (0.625-5mg) has gained significant traction among dermatologists and the biohacker community as a more convenient and potentially more effective alternative to topical application, particularly for individuals who find the topical formulation inconvenient or who experience scalp irritation. Minoxidil is a potassium channel opener that acts on ATP-sensitive potassium channels in vascular smooth muscle cells, causing vasodilation. When applied topically or taken orally, it is converted to its active metabolite minoxidil sulfate by the enzyme sulfotransferase (SULT1A1) in hair follicle outer root sheath cells. The sulfated form opens potassium channels in dermal papilla cells and vascular smooth muscle surrounding hair follicles, increasing local blood flow and nutrient delivery. Beyond vasodilation, minoxidil upregulates vascular endothelial growth factor (VEGF) expression, extends the anagen (growth) phase of the hair cycle, increases follicle size, and stimulates the transition of resting follicles from telogen into anagen. It also has anti-fibrotic properties that may benefit the perifollicular environment. Notably, minoxidil's hair growth effects are androgen-independent, making it effective regardless of DHT levels and complementary to 5-alpha reductase inhibitors like finasteride.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Subcutaneous injection is the standard delivery method. Some users also administer intranasally for more direct CNS effects. Amidate forms (NA-Semax and NA-Selank) have enhanced stability and duration. Conservative cognitive support 100-200mcg total blend Once daily (morning) SubQ or intranasal Standard protocol 200-400mcg total blend Once daily SubQ Enhanced protocol 400-500mcg total blend

Source: peptide-db.com ↗
Side effects

Common Side Effects

Hepatic stress with elevated liver enzymes (ALT, AST) -- moderate severity, dose- and duration-dependent HDL cholesterol suppression (significant, often 30-50% reduction) LDL cholesterol elevation Suppression of endogenous testosterone production via HPG axis negative feedback Mild gastrointestinal discomfort or nausea Back pumps (lower back tightness during exercise, common with 17-alpha-alkylated compounds) Oily skin and mild acne Decreased appetite in some users

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

02
Peptide Therapy Guide Editorial Team

Vilon Overview, Dosing & Safety | Peptide Database

Vilon (KE) KE Dipeptide | Thymus Immune Bioregulator Community Research Join others researching Vilon — share findings, ask questions, and learn from real experiences Vilon is a Khavinson bioregulator dipeptid…

Read guide →